NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.
Invest in Vita Imaging
Medical Device Company Developing Breakthrough Skin Cancer Detection in Real Time
Projected size of the Global Cancer Diagnostics Market
Invested in
commercialization
of the AURA
Over 20 years R&D by BCCA and UBC
Our award-winning AURA™ device helps detect skin cancer in two seconds
Americans will develop skin cancer before age 70
Die of skin cancer in the U.S. every hour
Annual cost for treating all skin cancers: about $4.8B for nonmelanoma and $3.3B for melanoma
People are treated for skin cancer yearly.
9,500 people are diagnosed with skin cancer every day
However, most healthcare providers still rely on visual inspection of suspicious lesions, sometimes with dermatoscopes for magnification, to identify potential skin cancer concerns, leading many physicians to excise or biopsy lesions as a precautionary procedure. These biopsies cost an estimated $1.6B annually and 95% of suspicious lesions are later found to be benign.
“WHEN DETECTED EARLY, THE FIVE YEAR SURVIVAL RATE FOR MELANOMA IS 94%”
Our licensed, patent-protected diagnostics platform capable of generating accurate, objective results in real-time
Vita Imaging believes there is an urgent need for physician support tools such as AURA™, which can improve diagnostic accuracy and significantly reduce the need for invasive and costly biopsies. AURA™ works by utilizing proven Raman spectroscopy technology to differentiate between benign and malignant lesions, and provide nearly instantaneous results. It’s also non-invasive and requires little training to use, meaning it can be quickly and easily deployed in any dermatological clinic.
Meet AURA™
The AURA product is pre-FDA approval and is not yet available in the market.
Skin Cancer: The Solution
Presenting the Vita Imaging AURA
AURA: Three Easy Steps
Power up the AURA Imaging Device
Scan the Affected Area Using the Light Probe Instant Result ( < 1.5sec)
Review Display for Diagnosis & Recommended Next Steps
AURA Development –Past to Present
Over 20 years R&D by British Columbia Cancer Agency (BCCA), University of British Columbia, Verisante.
Industry & Research investment of $ 2 0 million to commercialize AURA
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
Retail product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
AURA Development –Past to Present
Over 20 years R&D by British Columbia Cancer Agency (BCCA), University of British Columbia, Verisante.
Industry & Research investment of $ 2 0 million to commercialize AURA
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
Retail product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
Proven Technology
from the British Columbia Cancer Agency and the University of British Columbia
of extensive research and development
a comprehensive patent portfolio
To date, the AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Through this process, we believe that AURA™ has strong potential to exceed FDA benchmarks, ideally paving the way for full clearance and commercialization as a Class 3 medical device.
Featured On
What’s Next
REGULATORY & GO-TO-MARKET TIMELINE: The Road Ahead
FDA Submission September BriteLab (OEM)
US Clinical Study August-December Manufacturing Audit
Multi-site Clinical & MRMC Studies
FDA Approval Class 3
US Launch AURA
EU, UK AURA
Asia (select markets) AURA
*AURA is a Class 3 PMA Device. FDA approval is, on average, 3 years for this device class.
Why Invest
Helping Save Lives One Diagnosis at a Time
Our Experienced Team is Unmatched
Thinh Tran • CEO & Chairman
Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018…
Maria Victoria ReadeCOO
Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech…
Dzung Kim Tran WrightCFO
Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology…
We Invite You to Invest and Secure Equity in Vita Imaging!
Join us as we aim to deploy our technology where it’s needed most and defy cancer on a worldwide scale.
The AURA product is pre-FDA approval and is not yet available in the market.